These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 26756205)

  • 21. Angiogenesis in glioblastoma multiforme: navigating the maze.
    Linkous AG; Yazlovitskaya EM
    Anticancer Agents Med Chem; 2011 Oct; 11(8):712-8. PubMed ID: 21707499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anti-angiogenic strategies in glioblastoma].
    Guillamo JS
    Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
    Rose SD; Aghi MK
    Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
    [No Abstract]   [Full Text] [Related]  

  • 24. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
    Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating intratumoral heterogeneity from spatiotemporal data.
    Rutter EM; Banks HT; Flores KB
    J Math Biol; 2018 Dec; 77(6-7):1999-2022. PubMed ID: 29737395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy.
    Tuettenberg J; Grobholz R; Seiz M; Brockmann MA; Lohr F; Wenz F; Vajkoczy P
    J Cancer Res Clin Oncol; 2009 Sep; 135(9):1239-44. PubMed ID: 19277712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Go or grow': the key to the emergence of invasion in tumour progression?
    Hatzikirou H; Basanta D; Simon M; Schaller K; Deutsch A
    Math Med Biol; 2012 Mar; 29(1):49-65. PubMed ID: 20610469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ["Vicious circles" of glioblastoma tumors: vascularization and invasiveness].
    Szala S; Jarosz M; Smolarczyk R; Cichoń T
    Postepy Hig Med Dosw (Online); 2012 Nov; 66():888-900. PubMed ID: 23175345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Angiogenesis and anti-angiogenic strategies for glioblastoma].
    de Boüard S; Guillamo JS
    Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
    Vymazal J; Wong ET
    Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
    Wang L; Liu Q; Zhao H; Cui K; Yao L; Nie F; Jin G; Hao A; Wong ST
    J Neurosci Res; 2013 Jan; 91(1):128-37. PubMed ID: 23115024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties.
    Clavreul A; Guette C; Faguer R; Tétaud C; Boissard A; Lemaire L; Rousseau A; Avril T; Henry C; Coqueret O; Menei P
    J Pathol; 2014 May; 233(1):74-88. PubMed ID: 24481573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype.
    Rajcevic U; Petersen K; Knol JC; Loos M; Bougnaud S; Klychnikov O; Li KW; Pham TV; Wang J; Miletic H; Peng Z; Bjerkvig R; Jimenez CR; Niclou SP
    Mol Cell Proteomics; 2009 Nov; 8(11):2595-612. PubMed ID: 19674965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Speed Switch in Glioblastoma Growth Rate due to Enhanced Hypoxia-Induced Migration.
    Curtin L; Hawkins-Daarud A; van der Zee KG; Swanson KR; Owen MR
    Bull Math Biol; 2020 Mar; 82(3):43. PubMed ID: 32180054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of fractal-shaped outer boundary of glioblastoma multiforme on drug delivery.
    Samioti SE; Benos LT; Sarris IE
    Comput Methods Programs Biomed; 2019 Sep; 178():191-199. PubMed ID: 31416549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling treatment-dependent glioma growth including a dormant tumor cell subpopulation.
    Böttcher MA; Held-Feindt J; Synowitz M; Lucius R; Traulsen A; Hattermann K
    BMC Cancer; 2018 Apr; 18(1):376. PubMed ID: 29614985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.